Physician profile
Matthew J Price
NPI 1659343945
$2,308,175.56
in general payments reported to CMS, 2019-2025
46 companies · $1.3M in 2025
The $1.3M reported for 2025 was more than what 99% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $171K · 2020: $112K · 2021: $135K · 2022: $219K · 2023: $163K · 2024: $186K · 2025: $1.3M.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $1.1M · Consulting Fee: $330K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $117K · Travel and Lodging: $73K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $33K · Food and Beverage: $29K · Grant: $3,175 · Education: $29.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $1,087,384.93 |
| Consulting Fee | $329,873.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $116,693.75 |
| Travel and Lodging | $73,388.84 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $32,625.00 |
| Food and Beverage | $29,005.45 |
| Grant | $3,175.00 |
| Education | $29.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,335,957.11 | 2019-2025 | General - Therapies, Watchman Access System, Watchman Flx |
| Abbott Laboratories | $335,195.03 | 2019-2025 | Triclip, Mitraclip, Amplatzer Amulet |
| W. L. Gore & Associates, INC. | $175,931.28 | 2019-2025 | Gore Cardioform Septal Occluder, Product In Development, Gore Cardioform Asd Occluder |
| Philips North America LLC | $146,476.89 | 2019-2025 | (9520) Igt Devices Undivided, Igt Devices Undivided, (Bh4) Igt Devices Undivided |
| Shockwave Medical, INC | $140,376.38 | 2019-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave E8 Peripher |
| Medtronic, INC. | $45,010.48 | 2020-2025 | Ffrangio, Onyx Frontier, Acist Rxi System |
| Medtronic Vascular, INC. | $32,826.98 | 2019-2020 | |
| Cordis US Corp. | $20,470.78 | 2025 | Selution Slr Pta, Selution Slr Ptca |
| Baylis Medical Company INC | $14,046.69 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $13,118.70 | 2019-2023 | Andexxa |
| Cathworks, INC. | $9,005.04 | 2022-2025 | Ffrangio |
| Chiesi USA, INC. | $8,101.39 | 2019-2025 | Kengreal, Cleviprex |
| Acist Medical Systems, INC. | $7,334.46 | 2019-2025 | |
| Biosense Webster, INC. | $7,125.00 | 2020-2025 | Carto 3 |
| Biotronik INC. | $6,493.94 | 2019-2025 | Orsiro Mission, Trapit, Nhancer Rx |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acutus Medical, INC. | $3,107.85 | 2020-2022 | |
| Edwards Lifesciences Corporation | $2,484.16 | 2019-2025 | Pascal, Sapien 3 Ultra Resilia |
| Gentuity, LLC | $1,661.19 | 2024-2025 | Gentuity Hf-Oct Imaging System, Vis-Rx, Vis-Rx Prime |
| Cook Medical LLC | $557.60 | 2019-2022 | |
| Cardiovascular Systems INC. | $550.59 | 2021-2022 | |
| Asahi Intecc USA, INC. | $540.48 | 2019-2025 | Asahi Coronary Wires, Asahi Ptca Guide Wire |
| Abiomed | $395.59 | 2022-2025 | Impella |
| Teleflex LLC | $181.93 | 2022-2024 | Guideliner |
| Novartis Pharmaceuticals Corporation | $166.58 | 2020-2025 | |
| Reflow Medical INC | $149.13 | 2023-2024 | |
| Pfizer INC. | $149.00 | 2019-2025 | |
| Inari Medical, INC. | $110.35 | 2022-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Terumo Medical Corporation | $96.25 | 2022-2023 | Glidewire |
| E.R. Squibb & Sons, L.L.C. | $80.18 | 2021-2024 | Eliquis |
| Recor Medical INC | $56.24 | 2025 | Paradise Ultrasound Renal Denervation System |
| Amgen INC. | $44.23 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $42.39 | 2021-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $40.22 | 2019 | |
| Kestra Medical Technology Services, INC. | $38.53 | 2024 | Assure Wcd |
| Ancora Heart, INC. | $30.30 | 2022 | |
| Cranial Technologies, INC | $30.02 | 2022-2023 | Doc Band |
| Regeneron Healthcare Solutions, INC. | $29.82 | 2024 | Evkeeza |
| Novo Nordisk INC | $24.03 | 2023 | Rybelsus, Ozempic |
| Trevena, INC. | $24.01 | 2022 | |
| Heartflow, INC. | $22.47 | 2025 | |
| Livanova USA, INC. | $19.94 | 2023 | Lifesparc |
| Medacta USA, INC. | $19.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.68 | 2023 | Jardiance |
| Cardiva Medical, INC. | $17.92 | 2025 | Optowire |
| Inspire Medical Systems, INC. | $16.73 | 2025 | Inspire |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,350.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.